Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: November 30, 2022 Report Code: GDGMDHC22394IDB-ST

Select Item

Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. The Small-Cell Lung Cancer market research report provides comprehensive information on the therapeutics under development for SCLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for SCLC and features dormant and discontinued projects.

SCLC Pipeline Products Market Segmentation by Targets

The key targets in the SCLC pipeline products market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, DNA Topoisomerase I, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Delta Like Protein 3, Poly [ADP Ribose] Polymerase 1, Leukocyte Surface Antigen CD47, Poly [ADP Ribose] Polymerase 2, CD3, and Lysine Specific Histone Demethylase 1A, among others. Programmed Cell Death Protein 1 was the leading target in the pipeline.

SCLC Pipeline Products Market Analysis by Targets

SCLC Pipeline Products Market Analysis by TargetsFor more target insights into the SCLC pipeline products market, download a free report sample

SCLC Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the SCLC pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, DNA Topoisomerase I Inhibitor, Cytotoxic To Cells Expressing Delta Like Protein 3, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Leukocyte Surface Antigen CD47 Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, CD3 Agonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor, among others. Programmed Cell Death Protein 1 Antagonist was the leading MoA in the market.

SCLC Pipeline Products Market Analysis by MoA

SCLC Pipeline Products Market Analysis by MoA

For more MoA insights into the SCLC pipeline products market, download a free report sample

SCLC Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the SCLC pipeline products market are intravenous, oral, subcutaneous, intravenous drip, parenteral, intratumor, intraperitoneal, intravesical, intramuscular, and inhalational, among others. Intravenous was the most preferred route for administration.

SCLC Pipeline Products Market Analysis by RoA

SCLC Pipeline Products Market Analysis by RoA

For more RoA insights into the SCLC pipeline products market, download a free report sample

SCLC Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the SCLC pipeline products market are small molecule, monoclonal antibody, monoclonal antibody conjugated, gene-modified cell therapy, fusion protein, synthetic peptide, biologic, cell therapy, oligonucleotide, and gene therapy, among others. The leading molecule was small molecule.

SCLC Pipeline Products Market Analysis by Molecule Types

SCLC Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the SCLC pipeline products market, download a free report sample

SCLC Pipeline Products Market - Competitive Landscape

Some of the leading companies in the SCLC pipeline products market are AstraZeneca Plc, Merck & Co Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Henlius Biotech Inc, Akeso Inc, BeiGene Ltd, Innovent Biologics Inc, and Pfizer Inc.

SCLC Pipeline Products Market Analysis by Companies

SCLC Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the SCLC pipeline products market, download a free report sample

SCLC Pipeline Products Market Report Overview

Key Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, DNA Topoisomerase I, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Delta Like Protein 3, Poly [ADP Ribose] Polymerase 1, Leukocyte Surface Antigen CD47, Poly [ADP Ribose] Polymerase 2, CD3, and Lysine Specific Histone Demethylase 1A
Key Mechanisms of Action Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, DNA Topoisomerase I Inhibitor, Cytotoxic To Cells Expressing Delta Like Protein 3, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Leukocyte Surface Antigen CD47 Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, CD3 Agonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intravenous Drip, Parenteral, Intratumor, Intraperitoneal, Intravesical, Intramuscular, and Inhalational
Key Molecule Type Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Synthetic Peptide, Biologic, Cell Therapy, Oligonucleotide, and Gene Therapy
Leading Companies AstraZeneca Plc, Merck & Co Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Henlius Biotech Inc, Akeso Inc, BeiGene Ltd, Innovent Biologics Inc, and Pfizer Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

23andMe Holding Co.
Abbisko Cayman Limited
AbbVie Inc
ADC Therapeutics SA
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Aileron Therapeutics Inc
Akeso Inc
Algernon Pharmaceuticals Inc
Alkermes Plc
Allogene Therapeutics Inc
Alphamab Oncology
Amgen Inc
Amphivena Therapeutics Inc
Andarix Pharmaceuticals Inc
Apollomics Inc
Applied Research using OMIC Sciences SL
Arcellx Inc
Ariceum Therapeutics GmbH
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Athenex Inc
Auransa Inc
Autolus Therapeutics Plc
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Bio-Thera Solutions Ltd
BioAtla Inc
Biogenera SpA
BioLineRx Ltd
BioNTech SE
Biotheus Inc
Boehringer Ingelheim International GmbH
Bolt Biotherapeutics Inc
BrightGene Bio-Medical Technology Co Ltd
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
Cardiff Oncology Inc
Carrick Therapeutics Ltd
Celcuity Inc
Celldex Therapeutics Inc
Centrymed Pharmaceutical Inc
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chiome Bioscience Inc
Clarity Pharmaceuticals Ltd
Compass Therapeutics Inc
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Culnexin Therapeutics LLC
Curis Inc
Cybrexa Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Daiichi Sankyo Co Ltd
Duality Biologics (Shanghai) Co Ltd
Dyadic International Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
EpicentRx Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Esanex Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FatiAbGen Corp
Fujifilm Holdings Corp
G1 Therapeutics Inc
Genelux Corp
Genexine Inc
Genmab AS
Genprex Inc
GI Innovation Co Ltd
Gilead Sciences Inc
Glycotope GmbH
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou DAC Biotech Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
Hibercell Inc
Hillstream BioPharma Inc
Horizon Therapeutics Plc
Hutchison MediPharma Ltd
ImaginAb Inc
Imago BioSciences Inc
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
Immunocore Holdings Plc
IMPACT Therapeutics Inc
Incyte Corp
Inhibrx Inc
Innovent Biologics Inc
Inspirna Inc
Ipsen SA
Jacobio Pharmaceuticals Group Co Ltd
JenKem Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
Jubilant Therapeutics Inc
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Kezar Life Sciences Inc
Kintor Pharmaceutical Ltd
Kronos Bio Inc
L&L Biopharma Co Ltd
Lee's Pharmaceutical Holdings Ltd
Legend Biotech Corp
LegoChem Biosciences Inc
Lepu Biopharma Co Ltd
LintonPharm Co Ltd
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Lyvgen Biopharma Ltd
MabVax Therapeutics Holdings Inc
Mabwell Shanghai Bioscience Co Ltd
MacroGenics Inc
MAIA Biotechnology Inc
Maxinovel Pharmaceuticals
MaxiVAX SA
Merck & Co Inc
Merck KGaA
Moderna Inc
Mologen AG
Monte Rosa Therapeutics Inc
MultiVir Inc
Nanjing CART Medical Technology Co Ltd
Nanology LLC
NewBio Therapeutics Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Northlake International LLC
Novartis AG
Novelty Nobility Inc
NOX Pharmaceuticals Inc
Omega Therapeutics Inc
OncoFusion Therapeutics Inc
Oncorus Inc
OneThree Biotech Inc
Ono Pharmaceutical Co Ltd
Oryzon Genomics SA
Oxford BioTherapeutics Ltd
Pacylex Pharmaceuticals Inc
PCG-Biotech Co Ltd
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Pleco Therapeutics BV
Plexium Inc
Plexxikon Inc
PNB Vesper Life Science Pvt Ltd
Prelude Therapeutics Inc
Processa Pharmaceuticals Inc
ProLynx LLC
Propanc Biopharma Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qurient Co Ltd
Rapa Therapeutics LLC
RAPT Therapeutics Inc
RayzeBio Inc
Recombio SL
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
RNR BioMedical Inc
Salubris Biotherapeutics Inc
Sanofi
Scancell Holdings Plc
SciTech Development LLC
Seagen Inc
SELLAS Life Sciences Group Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Huilun Life Science & Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
Simcha Therapeutics Inc
Sino Biopharmaceutical Ltd
SN BioScience
Sorrento Therapeutics Inc
SOTIO Biotech AS
Stcube Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Syros Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Targovax ASA
Tarveda Therapeutics Inc
Telomium SAS
Terns Pharmaceuticals Inc
Theratechnologies Inc
Thetis Pharmaceuticals LLC
Tmunity Therapeutics Inc
Transcenta Holding Ltd
Transcode Therapeutics Inc
TransThera Sciences (Nanjing) Inc
Treadwell Therapeutics Inc
TYK Medicines Inc
Vincerx Pharma Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
WindMIL Therapeutics Inc
Woomera Therapeutics Inc
Xbrane Biopharma AB
Xcovery Holding Co LLC
Xencor Inc
Y-mAbs Therapeutics Inc
Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Small-Cell Lung Cancer – Overview

Small-Cell Lung Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Small-Cell Lung Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Small-Cell Lung Cancer – Companies Involved in Therapeutics Development

Small-Cell Lung Cancer – Drug Profiles

Small-Cell Lung Cancer – Dormant Projects

Small-Cell Lung Cancer – Discontinued Products

Small-Cell Lung Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets in the SCLC pipeline products market?

    The key targets in the SCLC pipeline products market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, DNA Topoisomerase I, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Delta Like Protein 3, Poly [ADP Ribose] Polymerase 1, Leukocyte Surface Antigen CD47, Poly [ADP Ribose] Polymerase 2, CD3, and Lysine Specific Histone Demethylase 1A, among others.

  • What are the key mechanisms of action in the SCLC pipeline products market?

    The key mechanisms of action in the SCLC pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, DNA Topoisomerase I Inhibitor, Cytotoxic To Cells Expressing Delta Like Protein 3, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Leukocyte Surface Antigen CD47 Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, CD3 Agonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor, among others.

  • What are the key routes of administration in the SCLC pipeline products market?

    The key routes of administration in the SCLC pipeline products market are intravenous, oral, subcutaneous, intravenous drip, parenteral, intratumor, intraperitoneal, intravesical, intramuscular, and inhalational, among others.

  • What are the key molecule types in the SCLC pipeline products market?

    The key molecule types in the SCLC pipeline products market are small molecule, monoclonal antibody, monoclonal antibody conjugated, gene-modified cell therapy, fusion protein, synthetic peptide, biologic, cell therapy, oligonucleotide, and gene therapy, among others.

  • Which are the leading companies in the SCLC pipeline products market?

    Some of the leading companies in the SCLC pipeline products market are AstraZeneca Plc, Merck & Co Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Henlius Biotech Inc, Akeso Inc, BeiGene Ltd, Innovent Biologics Inc, and Pfizer Inc.

Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more